fbpx
September 12, 2020

NfL Blood Biomarker Captures Suboptimal Treatment Response in MS NfL Blood Biomarker Captures Suboptimal Treatment Response in MS

Measuring serum levels of neurofilament light chain (NfL) is an effective way of detecting disease activity and the need to optimize treatment in patients with multiple […]
September 12, 2020

App for MS Aims to Capture Elusive Signals of Progression App for MS Aims to Capture Elusive Signals of Progression

Investigators in Switzerland are testing an application for smartphones that they hope will elucidate subtle signs of disease progression in multiple sclerosis (MS)—beyond what standard imaging […]
September 12, 2020

Lessons for Patients With MS and COVID-19 Lessons for Patients With MS and COVID-19

Two important lessons about managing patients with multiple sclerosis (MS) and COVID-19 have emerged from a hospital clinic in Madrid that managed COVID-infected patients with MS […]
September 12, 2020

Satralizumab Reduces Risk of Severe NMOSD Relapse Satralizumab Reduces Risk of Severe NMOSD Relapse

Compared with placebo, satralizumab reduces the risk of severe relapse in patients with neuromyelitis optica spectrum disorder (NMOSD), according to investigators. The drug also was associated […]
September 12, 2020

Exposure to DMT May Delay Disability Accumulation in Primary Progressive MS Exposure to DMT May Delay Disability Accumulation in Primary Progressive MS

For patients with primary progressive multiple sclerosis (MS), longer exposure to disease-modifying therapy (DMT) may delay the time at which a patient is restricted to a […]
September 11, 2020

Cardiovascular Risk Factors Linked to Brain Atrophy in MS Cardiovascular Risk Factors Linked to Brain Atrophy in MS

Dr Raffaello Bonacchi The presence of cardiovascular risk factors in patients with multiple sclerosis (MS) is associated with a greater degree of brain atrophy even in […]
September 11, 2020

In MS, Serious AEs More Common in Rituximab vs Ocrelizumab In MS, Serious AEs More Common in Rituximab vs Ocrelizumab

Serious side effects make up the majority of adverse effects of rituximab and ocrelizumab in patients with multiple sclerosis (MS), a new postmarketing analysis finds, and […]
September 11, 2020

Smoking Increases Risk of High Plasma NfL Levels in MS Smoking Increases Risk of High Plasma NfL Levels in MS

A new study has found that patients with multiple sclerosis (MS) who smoke cigarettes regularly have an increased risk of higher plasma neurofilament light levels (pNfL), […]
September 11, 2020

Portable Low-Field MRI Promising in Critically Ill Patients Portable Low-Field MRI Promising in Critically Ill Patients

A portable, low-field magnetic resonance imaging (MRI) device provides convenient, safe, and accurate bedside neuroimaging in critically ill patients, results from a small new study suggest. […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0